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BeveraAcuteHeartFellure
D. Pellerin, P.Demolis, J.L. Teboul, C. Veyrat, A. Berdeaux, J.F. Giudicelli,
S. Witchitz. The University Heap/ta/of Blcetre, La Kremlin Bicetra, France
Since Iinaidomine (L) isadirect nitric oxide donor it may not induce tolerance.
To evaluate the effects of L on cardiac and brachial hemcdynamics and the
development of L tolerance during a 46-hour period, 10 patients (62 +
10 yrs) with dilated cardiomyopathy and acute heatt failure received step
increaae doses of L (0.5 r.@kg/min) started > 4 hours after insertion of
the pulmonary artery catheter without any other drug. The maximal dose
of L was defined as the lowest of the 2 incremented doses responsible
for a mean pulmonaty artery wedge pressure (MPWP) or a cardiac index
(Cl) change Ie.sathan 10% or for a mean blood presaure (MBP) below 60
mmHg. Restdk: At the maximal dose of L (2.3 + 1.3 @k@mln, range 0.5-5
wYl@mln) all parameters but heart rate changed significantly from baseilne.
Cl was 2.44 + 0.61 I/mIn/m* from 1.5 + 0.3, MBP 69,+ 6 mmHg from83
+ 9, Systemicvascularresistance(SVR) 2141 + 448 dynes.s.cm-s from
3719 + 1058, MPWP 17 + 9 mmHg from 30 + 8, Right atrial pressure
(RAP) S + S mmHg from 16&8, Pulmonary vascular resistance 381 + 13
dynes.s.cm-5 from 661 + 326, Pulmonary artery saturation 56.8 + 9.6%
from 45.9 + 10.5, Brachial atiery diameter 4.5 + 0.3 mm from 4.1 + 0.1,
Brachial artery blood flow 107.5+ 35.6 mUmlnfrom 75.7+ 31.3 (2D pulsed
Doppler system). At the maximal dose of L, the study was stopped in 3
patients dueto headacheor noimprovementin Cl andMPWP. In 7 patients
the maximal dose of L was continuously infuaed and ikeeffects persisted for
24 hours, Ltolersnce developed in 2 patients (after 25 and 34 hour infusions
mspestively) characterizedbyincreased dyepnea, MPWP and RAP despite
small decreaseIn Cl and SVR. Corrcluskrrr:L improves cardiac and brachial
hernodynamiosInpatients wlthsevere acute haartfailura. However tolerance
to maintained high doses of L may develop in some patients after 24 hours.
m1084148 BeneflolalAcuteHemodynamlcEffeotofEndoaenousAdenosineAccumulationin
Patie;~ withChronicHeertFailure
L. Cortigiani, M. Baroni, E. Picano, C. Palmierf, M. Ravani, A. Boni,
E. Nannini, A. Biagini. Cardiovascular Unit, Castelnuovo Qarfagnana
Hospital, Lucca, Italy CNR Institute of Clinical Phyalo@rK Plea, Italy
Exogenouely administered adenosine reduces vascular resistance and in-
creaeee cardiac output in normal subjects end in patients with pulmonary
hypertension orend-etage biventricular heart feilure. Endogenous adenosine
accumulation can be provoked by dipyridamole (DIP). The aim of the study
wee to assess the acute effects of endogenous adenosine accumulation in-
duced by an infra-low dose (0.28 mg/Kg over 4’) DIP infusion on systemic
and pulmonary hemodynamics in patients with severe chronic heart failure.
Twenty patiente (11 men and 9 women, mean age ~ & 8 years) with chronic
heart failure (mean ejection fraction 25 + 5%) underwent right hearicatheter-
ization. Hemodynamic variables were meesurad before end after infra-low
dose DIP infusion. After DIP there was a mild increase in heart rate (rest =78
+ 18ve DIP= 81 + 14 bpm, p= 0.03) and reduction in mean systemic blood
pressure (rest =98 & 17ve DIP= 91 l 16 mm Hg, p < 0.001). DiP increased
cardiac output (rest =4.5 & 1 vs DIP 5.7+ 1.3 Vmin,p < 0.001) and cardiac
index (rest= 2.5 &O.6ve DIP= 3.1 +0.7 l/mirdm2,p e 0.001), and decreased
syatemic vascular resistance (rest= 30 + 11.8vs DIP = 22.6+ 9.8 Wads
unit, p < 0.001). Moreover, DIP reduced mean pulmonaty artery pressure
(rest =31 +12 vs DIP= 28 + 13 mm Hg, p < 0.01) and pulmonary vascular
resistance (rest = 4.3 + 2.6 vs DIP = 2.9 + 2.1 Woods unit, p c 0.001),
without changes in mean pulmonary wedge preasure (rest = 20 + 9 vs DIP
=18 + 10 mm Hg, p = NS). There was a significant correlation between per-
cent decrease from baseline in pulmonary and systemic vascular resistance
(r= 0.68; p = 0.002) after DIP. Acute endogenous adenoaine accumulation
induced by infra-low doee DIP improves the hemodynamic profile decreasing
pulmonary and vascular resistance and increasing cardiec index in patients
with severe chronic heert failure.
a108538 AbnormalCardiacFibroblastaUnmeakedByVesnarinone:A PossibieContributorto Heart
FaiiureinAorticRegurgitation
J.S. Ross, S.M. Goldfine, E.M. Herrold, J.S. Borer. The New York Hosp/ra/,
Come\l Madical Centec New York,NX USA
We have previously shown that, in experimental aortlc regurgitation (AR),
congestive heart failure (CHF) and death are preceded by exfenslve fibrob-
Iast (F)-mediatad primary fibrosis. Vesnarinone (VS) Is a K+ channel blocker
which 1) may reduce CHF hospitalizations and mortality and 2) affects F
morphology. To determine if VS may act In part by suppressing myocar-
dial fibrosis, we examined VS effects on cardiac F in culture. Cells were
enzymatically isolated from adult New Zealand White rabbits with anrJwith-
out surgically-induced severe chronic compensated AR and cultured for up
to 8 passages. Cultures were treated with sulfolane-solubilized VS (con-
centrations = 1 x 10-5M to 1 x IO-g M). F morphology and number were
assessed from normal (12 experiments) and AR (7 experiments) cultures;
various doses were tested in each experiment. No effect on F morphology
was seen et any concentradon. However, at 5 x 10-7M VS, normal F cell
number was 55% less than sulfolane cantrol (p= 0.03); at higher doses, cell
number Increased, peaking slightly above control. In contrast, in AR cells,
mmparable reductions (p < 0.02) were seen at low concentrations (down to
1 x 1O-SM);however,cell number increased but did not reach ~ntrol value,
even up to 1 x 10-5M. In situ labeling (3 experiments) suggest VS acts via
induction of apoptoais aince 5 x 10–7MVS-treatad cultures contained twioe
as many apoptotic cells as controls (p s 0.1). Thus, chronic AR alters F
biology, possibly contributing to CHF. Suppression of fibrosis by diminishing
F viability maybe partly responsible to clinical benefit of VS in chronic CHF.
[1085-39/ Aofti~R~urgitationis FraquentlyPreaentin
PatientsWithFamilialHyperchoiesterolemia
S. Mittal, J.S. Cohen, B.J. Clark, D.J. Rader, J.M. Wileon, S.E. Wiegere,
D.M. Kolansky. The Hospita/ofthe University of Pennsylvania, Phi/ade/phia,.
PA, USA
Familial hypercholesterolemia (FH) causes earfy atherosclerosis of theaonic
root (AoR) and aortic valve (AV) and extends into the origin of the coronary
arteries. We ‘aimed to define the spectrum of AoR and AV abnormalities in
these patients (pte).
Methods: We evaluated 32 pts with FH, age 3 to 45 years; 19 were
malea and 13 females. Mean cholesterol level was 560 mgldl (270-1082
mg/dl). Cardiac catheterization (with cartography) and/or echocardiography
was pettormed in 28 pts. Aortic regurgitation (AR) and stenosis (AS) were
graded in standerd fashion.
Results: A left ventricle to aorta gradient of 10-75 mmHg, predominantly
aupravelvular,was preaent in 8 (28%) pta. AR was present in 16 (57%) pts;
of these pts, 56% had at least moderate AR. A thickened AV, usually at the
ieaffet tips, was visualized in 78% of pts who underwent echocardiogrephy.
SO”+&of pta with AR had concomitant AoR disease, characterized by an
irregular, narrowed, thickened and calcified proximal aorta. AR was eeen
as a central andbr eccentric jet and appeared related to incomplete AV
coaptetion due to atheromatous deposition in the AoR and/or AV leaflets.
There was no association between age and the eeverify of AVabnormalitiea.
Moderate AR wee present even in the firat decade of life.
Conclusions: AR is the meet common AV abnormality in pts with FH. Pte
with FH should,be promptly screened for AR and eeriai evaluations of the AV
should be patformed when AR is present.
11085-40[ piaSmaAtria,NatriUreticpe@ideandBrain
NatriureticPeptideLevelsinChronicAortic
Regurgitation
J. Kanda, M. Suzuki, N. Takeuchi, K. Nakamura. Asahi Geners/Haspita/,
Aaahi, Japan
The purpose of this atudy was to estimate the value of the measurement of
plasma atrial natriuretic peptide (ANP) and brsin natriuretic peptide (BNP)
levels in chronic aortic regurgitation (AR). We measured plasma ANP and
BNP Ievals in 15 patients (pte) with chronic severe AR accompanied with
left ventricular dilatation. The pts were divided into two groups depending
